Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Upon entry into cells, remdesivir is metabolized into the nucleotide triphosphate GS-441524. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. It was developed as a treatment for filovirus infections such as Ebola virus disease and Marburg virus. Remdesivir was approved for treatment of COVID-19. Our product Remdesivir is a Pure chemical in Powder form for laboratory research use only, NOT FOR HUMAN OR PATIENT USE
Chemical Formula: C27H35N6O8P
Exact Mass: 602.2254
Molecular Weight: 602.58
Elemental Analysis: C, 53.82; H, 5.85; N, 13.95; O, 21.24; P, 5.14
Prodrug of GS-441524
Prodrug of GS441524
Prodrug of GS441524
InChi Code: InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
Remdesivir (GS-5734) is a potent antiviral agent. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h.
Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020 Apr 10. doi: 10.1007/s10067-020-05073-9. Epub ahead of print. PMID: 32277367.
Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020 Apr 6;12(4):e7560. doi: 10.7759/cureus.7560. PMID: 32269893; PMCID: PMC7138423.
Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020 Apr 2:101647. doi: 10.1016/j.tmaid.2020.101647. Epub ahead of print. PMID: 32247927; PMCID: PMC7151266.
Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020 Apr 1. doi: 10.1016/j.ijid.2020.03.071. Epub ahead of print. PMID: 32247050; PMCID: PMC7118633.
Reina J. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 [Remdesivir, the antiviral hope against SARS-CoV-2]. Rev Esp Quimioter. 2020 Apr 1:reina01apr2020. Spanish. doi: 10.37201/req/098.2020. Epub ahead of print. PMID: 32239125.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.